Effect of intrapleural perfusion chemotherapy on malignant pleural effusion in patients with non-small cell lung cancer

Xin-quan LI,Zi-ling LIU,Guan-ning SHANG
DOI: https://doi.org/10.13507/j.issn.1674-3474.2017.09.027
2017-01-01
Abstract:Objective To investigate the clinical effect of intrapleural hyperthermic perfusion chemotherapy on pleural effusion in patients with non-small cell lung cancer (NSCLC) and its safety.Methods Eighty NSCLC patients with pleural effusion were randomly divided into observation group and control group,with 40 patients in each group.Observation group received intrapleural hyperthermic perfusion chemotherapy with 40 mg/m2 cisplatin + 2 000 mL normal saline,and control group received intrapleural normothermic perfusion chemotherapy with 40 mg/m2 cisplatin + 2 000 mL normal saline for 1 h,once a week,totally for three times.The therapeutic effect and adverse reactions were compared between two groups in 1 month after treatment.Results The therapeutic effect was significantly higher in observation group (87.50%) than that in control group (65.00%) (P<0.05).The adverse reactions during treatment were in level Ⅰ to Ⅱ,and were relieved after symptomatic treatment.There were no significant differences in the incidences of gastrointestinal reaction,chest pain and bone marrow suppression between observation group (25.0%,25.0%,30.0%) and control group (35.0%,17.5%,37.5%) (P>0.05).Conclusion Intrapleural hyperthermic perfusion chemotherapy is effective and safe for pleural effusion in patients with NSCLC.
What problem does this paper attempt to address?